This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will KalVista Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in KalVista Pharmaceuticals.
Factors Setting the Tone for Oracle's (ORCL) Q3 Earnings
by Zacks Equity Research
Oracle (ORCL) is benefiting from increasing adoption of its product portfolio and synergies from strategic buyouts.
Broadcom (AVGO) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Broadcom (AVGO) extensive product portfolio is likely to positively impact the to-be-reported quarter's results.
Top Ranked Momentum Stocks to Buy for March 7th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 7th
KalVista Pharmaceuticals (KALV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
KalVista Pharmaceuticals (KALV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
KalVista Pharmaceuticals (KALV) Q1 Earnings Preview: What to Look Out For
by Zacks Equity Research
KalVista Pharmaceuticals (KALV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News For Oct 11, 2017
by Zacks Equity Research
Companies in the news are: CUDA,MRK,ANAB,HDSN
KalVista Pharmaceuticals (KALV) in Focus: Stock Jumps 6%
by Zacks Equity Research
KalVista Pharmaceuticals, Inc. (KALV) saw its shares rise 6% in the last trading session.